Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58–61.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumorangiogenesis. N Engl J Med. 2008;358:2039–2049.
   PubMed Web of Science ®Google Scholar
• Aprile G, Bonotto M, Ongaro E, et al. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs. 2013;73:2003–2015.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez RR, Rueda BR. Tumor angiogenesis regulators. Boca Raton (FL): CRC Press; 2013. ISBN: 978-1-4665-8097-8.
   Google Scholar
• Lamalice L, Houle F, Jourdan G, et al. Phosphorylation of tyrosine 1214 on VEGFR2 isrequired for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene. 2004;23:434–445.
   PubMed Web of Science ®Google Scholar
• Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2:123.
   PubMedGoogle Scholar
• Nwibo DD, Levi CA, Nwibo MI. Small molecule drugs; down but not out: a future for medical research and therapeutics. IOSR J Dental Med Sci (IOSR-JDMS). 2015;14:70–77.
   Google Scholar
• Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013;13:1187–1196.
   PubMed Web of Science ®Google Scholar
• Aprile G, Rijavec E, Fontanella C, et al. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014;7:1997–2006.
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1monoclonalantibodytargeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–787.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26:1230–1237.
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Song S, Lee JS, et al. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–655.
   PubMed Web of Science ®Google Scholar
• Cabuk D, Basaran G, Celikel C, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology. 2007;72:111–117.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–3976.
   PubMed Web of Science ®Google Scholar
• Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor2. Biochem Biophys Res Commun. 2006;345:438–445.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol. 2014;15:1224–1235.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Van Cutsem E, Oh SC, et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016;27:673–679.
   PubMed Web of Science ®Google Scholar
• Muro K, Oh SC, Shimada Y, et al. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. J Gastroenterol Hepatol. 2016;31:581–589.
   PubMed Web of Science ®Google Scholar
• Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014;32(15_suppl):4004.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529.
   PubMed Web of Science ®Google Scholar
• Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoSOne. 2013;8:e54014.
   PubMed Web of Science ®Google Scholar
• Li J, Quin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016. Epub Feb 16.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–3712.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomisedphase3 trial. Lancet Oncol. 2013;14:1077–1085.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523–3529.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–1618.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol. 2013;14:29–37.
   PubMed Web of Science ®Google Scholar
• Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progressionto first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015;26:724–730.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Takayuki Y, Cohn AL. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508.
   PubMed Web of Science ®Google Scholar
• Giampieri R, Caporale M, Pietrantonio F, et al. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? Crit Rev Oncol Hematol. 2016;100:99–106.
   PubMed Web of Science ®Google Scholar
• Kubicka S, Greil R, André T, et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol. 2013;24:2342–2349.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50:320–331.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453–459.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Fioravanti A, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104:1262–1269.
   PubMed Web of Science ®Google Scholar
• Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoSOne. 2013;8:e77117.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Loupakis F, Bocci G, et al. Biomarkers and response to bevacizumab–letter. Clin Cancer Res. 2014;20:1056–1057.
   PubMed Web of Science ®Google Scholar
• Sims TN, Gao B, Phillips R, et al. Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial. J Clin Oncol. 2015;33(3_suppl):638.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19:6614–6623.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870.
   PubMed Web of Science ®Google Scholar
• Zhu A, Ryoo B, Yen C, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study. J Clin Oncol. 2015;33(3_suppl):232.
   Web of Science ®Google Scholar
• Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome (PFO) results from the phase 3 REACH study. J Clin Oncol. 2015;33(15_suppl):4077.
   Google Scholar
• Eli Lilly and Company. Randomized, double-blind, placebo-controlled, Phase 3 study of ramucirumab and Best Supportive Care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma and elevated baseline Alpha-Fetoprotein (AFP) Following first-line therapy with sorafenib. [cited 2015 Jul 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT02435433. NLM identifier: NCT02435433
   Google Scholar
• Harding J, Bendell J, Fuchs C, et al. Emibetuzumab plus ramucirumab: simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study. J Clin Oncol. 2016;34(4_suppl):300.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Phase 1b study of 5-FU/FA and oxaliplatin (FOLFOX4) plus ramucirumab (LY3009806) in patients with advanced hepatocellular carcinoma. [cited 2015 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02069041. NCT02069041.
   Google Scholar
• Saif MW. Advanced stage pancreatic cancer: novel therapeutic options. Expert Rev Clin Pharmacol. 2014;7:487–498.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Phase II randomized, double-blind study of FOLFIRINOX plus ramucirumab versus FOLFIRINOX plus placebo in advanced pancreatic cancer patients: Hoosier Cance rResearch Network GI14-198. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT02581215
   Google Scholar
• Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.
   PubMedGoogle Scholar
• Pan Y, Zheng M, Zhong L, et al. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. Mol Cancer Ther. 2015;14:407–418.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. A phase I study of LY2801653 in patients with advanced cancer. [cited 2015 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01285037. NCT01285037.
   Google Scholar
• Eli Lilly and Company. A study of ramucirumab (LY3009806) or merestinib (LY2801653) in advanced or metastatic biliary tract cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02711553
   Google Scholar
• Eli Lilly and Company. Ramucirumab for advanced pre-treated biliary cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT02520141
   Google Scholar
• Goldsetin DA, Chen Q, Avert T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J Clin Oncol. 2015;33:112–118.
   Web of Science ®Google Scholar
• Goldstein DA, El-Rayes BF. Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer? Oncologist. 2015;20:981–982.
   PubMed Web of Science ®Google Scholar
• Bach PB. Ramucirumab for colon cancer and the problem of rising prices independent of benefits. Oncologist. 2015;20:983–984.
   PubMed Web of Science ®Google Scholar
• Fasola G, Aprile G, Pinto C. Balancing clinical progress with economic sustainability: in quest for a courageous solution. J Clin Oncol. 2015;33:3841–3842.
   PubMed Web of Science ®Google Scholar